Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | G305 + ID-LV305 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
G305 | G305 is a mixture of recombinant NY-ESO-1 and synthetic glucopyranosyl lipid A (GLA), which binds to TLR4 to target dendritic cells and stimulate the immune response (PMID: 31069460). | |||
ID-LV305 | LV305 | ID-LV305 is a modified lentiviral vector encoding human tumor-associated cancer-testis antigen (NY-ESO-1) which may stimulates immune response against NY-ESO-1-expressing tumor cells (PMID: 31227504). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02609984 | Phase II | Atezolizumab G305 + ID-LV305 | Trial of CMB305 and Atezolizumab in Patients With Sarcoma | Terminated | USA | 0 |